Arizona State Retirement System Has $5.31 Million Position in Insulet Co. (NASDAQ:PODD)

Arizona State Retirement System boosted its position in Insulet Co. (NASDAQ:PODD) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,343 shares of the medical instruments supplier’s stock after buying an additional 276 shares during the period. Arizona State Retirement System’s holdings in Insulet were worth $5,311,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in PODD. Integrated Wealth Concepts LLC boosted its position in shares of Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after acquiring an additional 43 shares in the last quarter. Glenmede Trust Co. NA grew its stake in Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after acquiring an additional 47 shares during the period. Graypoint LLC increased its holdings in shares of Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after acquiring an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 47 shares in the last quarter.

Insulet Stock Down 3.0 %

Shares of NASDAQ:PODD opened at $251.81 on Friday. The company has a market cap of $17.68 billion, a price-to-earnings ratio of 43.49, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The firm has a fifty day moving average price of $274.09 and a two-hundred day moving average price of $252.86. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PODD shares. Piper Sandler upped their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Citigroup raised their target price on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. Wells Fargo & Company upped their price target on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. TD Cowen raised their price objective on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday. They issued an “outperform” rating and a $340.00 target price for the company. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.